secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0001104659-24-008230
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Biosciences prices public offering of 9M shares at $12.50/share, raising $112.5M gross
--------------------------------------------------------------------------------

- Priced 9,000,000 shares of Series A common stock at $12.50/share; gross proceeds ~$112.5M before expenses.
- Underwriters granted 30-day option to purchase up to 1,350,000 additional shares at the offering price.
- Net proceeds to fund denifanstat Phase 3 program in NASH, TVB-3567 IND for acne, and general corporate.
- Offering closed January 30, 2024; Goldman Sachs, TD Cowen, and Leerink acted as joint book-running managers.
- All shares sold by Sagimet; no selling stockholders in the offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924008230/0001104659-24-008230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924008230/tm244525d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-008230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer